ReviewCancer medicine2023
Insights into the leveraging of GABAergic signaling in cancer therapy.
Review in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Systematic characterization of neurotransmitter receptor dysregulation identifies a neural-related prognostic signature associated with biochemical recurrence in prostate cancer.Translational andrology and urology · 2026Article
- Production of Gamma-Aminobutyric Acid by Levilactobacillus brevis AK19B: Strain Characterization and Process Optimization Using Box-Behnken Design.Probiotics and antimicrobial proteins · 2026Article
- Neurotransmitters in cancer: how receptor signaling and posttranslational modifications modulate tumor progression and offer new therapeutic targets.Cell communication and signaling : CCS · 2026Review
- The role of γ-aminobutyric acid and its receptor in metabolic reprogramming and tumor progression.Biochemistry and biophysics reports · 2026Review
- Multiplexed magnetic resonance imaging.Nature · 2026Article
- Development and Validation of a Genome-Wide Association Study Based Polygenic Risk Score for Prostate Cancer in an Asian Population.The world journal of men's health · 2026Article
- The influence of neuro-tumor interactions on tumorigenesis and therapeutic response.Experimental hematology & oncology · 2026Review
- Gamma-aminobutyric acid affects the tumor microenvironment and angiogenesis, promoting breast cancer progression.CytoJournal · 2026Article
- GABA treatment promoting cell apoptosis in meningioma correlates with EGFR/BCL-2/BAX axis.Journal of neuro-oncology · 2025Article
- Novel GABAAR antagonists target networked gene hubs at the leading edge in high-grade gliomas.Neuro-oncology · 2025Article
- The Functional Interplay among GAD2, GABRG2, and CACNA1G Genes in Cancers.Asian Pacific journal of cancer prevention : APJCP · 2025Review
- Cancer and neurotransmitter receptors.Chinese medical journal · 2025Review
- Neurotransmitter power plays: the synaptic communication nexus shaping brain cancer.Acta neuropathologica communications · 2025Review
- Metabolic signature of renal cell carcinoma tumours and its correlation with the urinary metabolome.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data.Exploration of targeted anti-tumor therapy · 2025Article
- The double role of GABAergic system in systemic tumors: an updated review.Frontiers in oncology · 2025Review
- Targeting GABA signaling in the tumor microenvironment: implications for immune cell regulation and immunotherapy resistance.Frontiers in immunology · 2025Review
- Integrative multi-omics and experimental analyses implicate PTK2 as a lorazepam-associated biomarker and potential therapeutic target in ovarian cancer.Frontiers in pharmacology · 2025Article
- Article
- Targeting the peripheral neural-tumour microenvironment for cancer therapy.Nature reviews. Drug discovery · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the brain of adult mammals. Several studies have demonstrated that the GABAergic system may regulate tumor development via GABA receptors, downstream cyclic adenosine monophosphate (cAMP) pathway, epithelial growth factor receptor (EGFR) pathway, AKT pathway, mitogen-activated protein kinase (MAPK) or extracellular signal-related kinases (ERK) pathway, and matrix metalloproteinase (MMP) pathway, although the exact mechanism is unclear. Pioneering studies reported that GABA signaling exists and functions in the cancer microenvironment and has an immunosuppressive effect that contributes to metastasis and colonization. This article reviews the molecular structures and biological functions of GABAergic components correlated with carcinogenesis, the mechanisms underlying GABAergic signaling that manipulate the proliferation and invasion of cancer cells, and the potential GABA receptor agonists and antagonists for cancer therapy. These molecules may provide an avenue for the development of specific pharmacological components to prevent the growth and metastasis of various cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.